OneMedNet (NASDAQ:ONMD) shares are trading lower on Tuesday, possibly on continued weakness after the stock rallied on Friday following a recent announcement about the next phase of its real-world data (RWD) platform.On Monday, the stock closed 26.55% lower.ONMD’s Growth Strategy Through RWD PlatformThe company is actively converting customer evaluations into commercial subscriptions, which are expected to drive predictable growth and millions in incremental annual recurring revenue (ARR). CEO Aaron Green n ...

Core Viewpoint - OneMedNet Corporation is advancing its commercial launch of the RWD Platform powered by Palantir Foundry, converting customer evaluations into subscriptions and reinforcing its position in the life sciences and healthcare sectors [1][4]. Group 1: Commercial Launch and Subscription Growth - The launch is driving rapid expansion of subscription contracts, including multi-year deals that represent millions in incremental recurring revenue [2]. - The OneMedNet iRWD™ network has over 2,130 healthcare sites, and as it scales, the subscription value increases due to greater scale, diversity, real-time access, and analytical depth [2][4]. Group 2: Customer Feedback and Platform Strengths - Customer feedback confirms the platform's strengths, including unmatched analytical depth, accelerated cohort feasibility, streamlined workflows, and faster onboarding of data partners [3]. - The platform provides near real-time access to comprehensive regulatory-grade multimodal RWD, enhancing study design and evidence generation [5][6]. Group 3: Investor Benefits - The commercial launch supports OneMedNet's high-margin recurring revenue model, with evaluation conversions to multi-year subscriptions expected to drive predictable growth and millions in incremental annual recurring revenue [4]. - Network expansion is anticipated to boost deal sizes and penetration in life sciences, AI, and research sectors, fueling sustained bookings [4]. Group 4: Company Overview and Industry Impact - OneMedNet is revolutionizing access to Real-World Data (RWD) through its iRWD™ platform, which harnesses data from over 2,130 healthcare sites, impacting drugmakers, medical device innovators, and AI developers [8]. - The company's proprietary AI also anonymizes data for other industries, such as finance and retail, enhancing project de-risking and secure data sharing [9].

Core Insights - OneMedNet Corporation has announced a strategic partnership with ViuHealth to enhance its Real-World Data (RWD) offerings, particularly in the autoimmune disease sector [1][2] Group 1: Partnership Details - The partnership will integrate ViuHealth's longitudinal autoimmune disease data into OneMedNet's iRWD™ platform, which is powered by Palantir Foundry, thereby increasing the scale and diversity of regulatory-grade RWD [2][6] - ViuHealth will provide ongoing data that captures patient journeys, treatment adherence, flares, and outcomes, which will support pharmaceutical partners in drug discovery and market strategies [3][4] Group 2: Market Opportunity - The autoimmune therapeutics market is projected to exceed $166 billion globally in 2026, indicating a significant opportunity for pharmaceutical and biotechnology companies to leverage the enriched datasets for drug development and regulatory evidence [3][14] - Autoimmune diseases affect approximately 8% of the U.S. population, representing tens of millions of individuals, creating strong demand for longitudinal real-world data in life sciences and digital health [5][14] Group 3: Revenue Growth Strategy - This partnership is expected to drive OneMedNet's subscription revenue growth by integrating high-value, disease-specific data into the iRWD™ platform, making it more attractive for ongoing subscriptions rather than one-time sales [4][14] - The collaboration aims to create predictable Annual Recurring Revenue (ARR) and enhance customer retention through expanded data feeds [14] Group 4: Company Positioning - OneMedNet is positioning itself as a trusted data infrastructure provider in specialty disease areas, reinforcing its role in the rapidly growing real-world data and AI-enabled healthcare markets [7][8] - The company aims to build repeatable, subscription-oriented data partnerships that generate continuous data flows, enhancing its ability to deliver relevant cohorts reflecting real-world patient journeys [7][14]

Core Insights - OneMedNet Corporation has entered a strategic data licensing agreement with Risorius Co., Ltd., focusing on AI-ready Real-World Data for neurotechnology applications [1][5] - The partnership aims to enhance subscription contracts and generate millions in recurring revenue for OneMedNet [1][5] Group 1: Agreement Details - The agreement was executed rapidly, indicating strong commercial alignment and immediate customer value [2] - Risorius has licensed large-scale EEG and PSG waveform data, which will support R&D and model validation for CNS-related studies [3][4] - The datasets will aid in the development of EEG-based digital biomarkers and an AI Co-Scientist platform [3][9] Group 2: Company Strengths - OneMedNet's data assets are characterized by high fidelity, substantial volume, and a structured curation process, making them attractive for R&D needs [4] - The company’s continuous delivery model and regulatory-grade data are seen as foundational for advancing CNS disorder solutions [5] - OneMedNet's iRWD™ platform taps into over 2,130 healthcare sites, providing diverse data that fuels innovation across various medical fields [6] Group 3: Industry Context - The partnership reflects a growing demand for high-quality datasets from AI-native companies in the neurotechnology sector [5] - Risorius aims to optimize CNS research and care delivery through its AI Co-Scientist platform, which translates EEG data into actionable insights [10]

Core Insights - OneMedNet Corporation achieved record bookings of $2.79 million in 2025, exceeding 2024 bookings by more than four times, indicating strong enterprise demand and a shift towards a recurring subscription model [1][7]. Booking Highlights - Total bookings reached $2.79 million in contract value for 2025, which is 4.1 times higher than the previous fiscal year [7]. - The company is experiencing larger deal sizes due to the expansion of average contract value driven by enterprise-scale AI models and life sciences engagements [7]. - There is a continued shift towards subscription models, with agreements signed in 2025 with Circle CVI and mlHealth360, indicating a growing pipeline extending into 2026 [7]. Product Offerings - The company is diversifying its product mix, focusing on data projects and subscription products, including curated bespoke datasets and pre-curated specialty datasets for various therapeutic areas [8]. - Subscription offerings include Palantir Agentic Search for data discovery, which accelerates feasibility analysis from weeks to minutes, and near real-time streaming healthcare data feeds [8]. Strategic Positioning - OneMedNet is entering 2026 with a strong momentum and a high-quality pipeline anchored by premium recurring revenue solutions powered by Palantir Foundry [5]. - The company believes its subscription solutions will drive a more predictable, higher-margin, and scalable revenue profile as it transitions to a predominantly subscription-based business model [9]. Market Demand - There is sustained strong inbound demand for multimodal, regulatory-grade datasets, which serve as foundational entry points into longer-term subscription relationships [14]. - The adoption of AI-enabled discovery workflows is enhancing customer stickiness and creating multiple expansion opportunities within existing accounts [14].

Core Insights - OneMedNet Corporation has announced that its Real-World Data (RWD) has supported mlHealth 360 in obtaining FDA 510(k) clearance for Scaida BrainCT-ICH, an AI-powered software for detecting intracranial hemorrhage from CT scans [1][4] Group 1: Company Overview - OneMedNet is a leading provider of regulatory-grade, AI-ready Real-World Data, utilizing over 2,130 healthcare sites through its iRWD™ platform [6] - The company focuses on delivering high-quality data that fuels innovation in drug development, medical devices, and AI applications [6] - OneMedNet's data includes longitudinal electronic medical records, diagnostic imaging, and clinical reports, which are crucial for regulatory submissions [3][4] Group 2: Product and Technology - Scaida BrainCT-ICH uses AI to analyze head CT images, identifying suspected intracranial hemorrhage in approximately 5.97 seconds, enhancing clinical triage and decision-making [2] - The FDA clearance of Scaida BrainCT-ICH underscores the increasing importance of Real-World Data in advancing medical AI, particularly in urgent clinical scenarios [5] Group 3: Partnerships and Collaborations - OneMedNet collaborates with mlHealth 360, providing high-quality, regulatory-grade data that allows the latter to focus on AI development without concerns about data quality or compliance [5] - The partnership highlights the value of high-quality data in accelerating healthcare innovations and improving patient outcomes [5][8] Group 4: Industry Impact - The milestone achieved by OneMedNet reinforces its position as a trusted data partner for life sciences and AI companies, indicating a growing reliance on high-quality data for successful regulatory outcomes [4][5] - The collaboration between OneMedNet and mlHealth 360 exemplifies the potential of AI in transforming medical imaging and enhancing clinical workflows [8][9]

Core Insights - OneMedNet Corporation has successfully delivered an anonymized Real-World Data feed representing 1.5 million patients and 4 million encounters to a healthcare data organization, marking a significant milestone in its subscription model [1][2][4] - The de-identified dataset contains over 1.49 billion datapoints, integrating comprehensive patient journeys and supporting advanced analytics and regulatory-grade research [2][4] - The company aims to transition customers to predictable annual recurring revenue streams, enhancing retention and long-term shareholder value [3][4] Company Overview - OneMedNet is focused on revolutionizing access to Real-World Data (RWD) through its iRWD™ platform, which taps into over 2,130 healthcare sites [5] - The company provides insights across various medical domains, including rare diseases, oncology, and cardiology, facilitating innovation for drugmakers and medical device companies [5] - Beyond healthcare, OneMedNet's AI technology anonymizes data for other industries such as finance and retail, showcasing its versatility [6]

Core Insights - PainReform Ltd. announced a name change and is expanding into diversified healthcare and AI-driven energy platforms, resulting in a 27.4% increase in share price to $1.02 in pre-market trading [1] Gainers - Acco Group Holdings Limited saw a significant gain of 219.4%, reaching $9.40 in pre-market trading [4] - Venus Concept Inc. increased by 72.2% to $2.48 [4] - Jaguar Health, Inc. rose 41.3% to $1.08 following a licensing agreement with Woodward Specialty [4] - ImmunityBio, Inc. gained 22.8% to $4.85, with preliminary net product revenue for Anktiva projected at approximately $113 million for fiscal 2025, marking a 700% year-over-year increase [4] - OneMedNet Corporation rose 14.2% to $0.9711 after a previous decline [4] - Brand Engagement Network, Inc. increased by 13.8% to $6.50 [4] - Springview Holdings Ltd rose 13.4% to $19.75 after a substantial 657% increase on Thursday [4] - Creative Global Technology Holdings Limited gained 10.7% to $4.22 after a 52% jump on Thursday [4] - Kopin Corporation increased by 8.1% to $3.20 [4] Losers - Callan JMB Inc. fell 20.7% to $3.33 after a 275% increase on Thursday due to a strategic agreement with Biostax Corp [4] - Erayak Power Solution Group Inc. decreased by 18.3% to $3.21 after an 18% rise on Thursday [4] - TryHard Holdings Limited dropped 16.4% to $6.35 following a 76% decline on Thursday due to a joint venture announcement [4] - iOThree Limited shares dipped 15% to $2.56 [4] - NOVONIX Limited fell 14% to $1.17 [4] - Moolec Science SA tumbled 13.1% to $6.69 after an 118% increase on Thursday [4] - High Roller Technologies, Inc. declined 12.9% to $20.64 after a 25% rise on Thursday [4] - Bonk, Inc. fell 10.4% to $3.55 after a 42% increase on Thursday due to acquisition news [4] - J B Hunt Transport Services Inc fell 4.2% to $197.86, reporting mixed financial results for the fourth quarter [4] - QXO Inc dipped 3.5% to $24.14 after announcing a $750 million stock offering and preliminary fourth-quarter net sales of $2.19 billion [4]

Core Insights - OneMedNet Corporation is focused on enhancing its platform and executing its strategic plan to drive growth in 2026, highlighted by the integration of Palantir's AI platform for accelerated development [1][5][7] Financial Performance - The company reduced its total liabilities by approximately $19.6 million, achieving a 75% reduction by the end of 2025 compared to December 31, 2024 [5] - Third quarter bookings increased eightfold year-over-year from 2024 to 2025, indicating strong demand for Real-World Data (RWD) [5] Platform Development - OneMedNet is set to launch an AI-driven multimodal subscription search platform in the new year, which is expected to transform data interaction for life sciences organizations [1][5] - The iRWD™ platform integrates multiple data modalities, providing a comprehensive view of patient health and enabling real-time tracking of patient journeys [5][10] Market Trends - There is a growing demand for large-scale RWD to train, validate, and monitor AI models, alongside an increasing interest in long-term, subscription-based data relationships [5][13] - The traditional model of lengthy clinical trials is being disrupted as regulators encourage the use of Real-World Evidence (RWE) for regulatory approval and post-market surveillance [6][13] Strategic Initiatives - The company plans to expand its platform in 2026 by introducing additional services related to data cohort building and delivery, as well as solutions focused on Health Economics and Outcomes Research (HEOR) [5][13] - OneMedNet aims to address the critical bottleneck in accessing healthcare data, positioning itself to unlock the estimated $868 billion AI-driven healthcare market by 2030 [13]

Core Insights - OneMedNet Corporation has demonstrated significant engagement and commercial traction at the RSNA Annual Meeting, indicating strong interest from hospitals, imaging centers, and life sciences innovators in its iRWD™ platform powered by Palantir Foundry [1][2][5] Company Overview - OneMedNet is a leading provider of regulatory-grade, AI-ready Real-World Data (RWD) networks, leveraging over 2,130 healthcare sites to deliver insights that drive innovation in healthcare [6] - The company focuses on providing high-quality, multimodal datasets that support healthcare providers and life sciences organizations in research and product development [5][6] Market Validation - The RSNA 2025 event validated OneMedNet's strategy amid rising demand for regulatory-grade RWD, with healthcare providers expressing a strong interest in utilizing their clinical data assets [2][3] - Life sciences companies and AI developers showed keen interest in the next-generation iRWD™ platform, highlighting its capabilities in providing large-scale, high-fidelity datasets and AI-enabled cohort discovery [4][5] Strategic Partnerships - Healthcare providers are looking for reliable and low-effort ways to engage in healthcare innovation and research, while life sciences organizations require scalable datasets to accelerate product development [5] - OneMedNet's efficient deployment model and opportunities for compliant data sharing were noted as key advantages for potential partners [3][5]